This holiday season, our #Dynamos came together to support The Wonderfund with a toy drive, ensuring children have gifts to open during the holidays. As the year comes to a close, we wish you and your loved ones a safe, joyful holiday season and a bright new year!
Dyne Therapeutics
Biotechnology Research
Waltham, Massachusetts 14,154 followers
Advancing life-transforming therapies for serious muscle diseases
About us
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. To view our community guidelines, click here: https://bit.ly/3BYPnpK
- Website
-
http://www.dyne-tx.com
External link for Dyne Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
1560 Trapelo Rd
Waltham, Massachusetts 02451, US
Employees at Dyne Therapeutics
-
Marcel Meth
SharePoint Consultant/Developer/Analyst (Intranets, Document Management, Collaboration & AIs)
-
Jason Rhodes
-
Michael Tobin
VP, Head of Technology at Dyne Therapeutics, improving patients' lives by straddling high tech and biotech in truly innovative life science…
-
Clarence J. Wang
VP, Head of Data Sciences
Updates
-
#RareDiseaseDay is getting closer! The Jett Foundation is hosting their 8th Annual Rare Disease Day event, which will include a panel discussion highlighting DMD community members sharing their experiences. Follow and visit their site to stay up to date: https://bit.ly/49tAICR
-
-
Have you watched our Joining Forces series yet? Explore insightful conversations with community members and #Dynamos that highlight our commitment to listening and learning as we work to advance potentially transformative therapeutics. Watch now: https://bit.ly/3MmFSWQ
-
-
Join us for an engaging webinar tomorrow hosted by SYSNAV Healthcare. Industry experts from Dyne Therapeutics, Roche, and TRiNDS will share valuable insights on strategies to unlock the potential of digital endpoints by using wearables in clinical trials. Register to hear the conversation: https://bit.ly/3ZxH0hr
-
-
As we celebrate Thanksgiving, we're especially thankful for our amazing team of #Dynamos, whose dedication fuels our mission to deliver life-transforming therapies for people living with neuromuscular diseases. Wishing everyone a Happy Thanksgiving!
-
Today we reported financial results for the third quarter of 2024 and provided a corporate update. Read here: https://bit.ly/4hHbW5T #investors #biotechnology #healthcare
-
-
We’re just a few months away from #RareDiseaseDay 2025. If you’re a healthcare professional, join Rare Disease Day's webinar on November 13 to learn more about rare diseases and help raise awareness: https://bit.ly/3BVB0FQ
-
We look forward to presenting at upcoming investor conferences this month. Learn more: https://bit.ly/3zHnp4e $DYN
-
-
We’re proud to sponsor the upcoming Little Steps Association for Duchenne and Becker Muscular Dystrophy patients bi-annual conference. Learn more about the organization: https://bit.ly/40weT32
-
-
We’re joining clinicians, researchers, and individuals living with Duchenne at the Action Duchenne Annual International Conference to discuss the latest advances in #DMD research. Check out this year’s agenda and be sure to catch us during the industry Q&A: https://bit.ly/3NTiArW #Duchenne #biotechnology
-